nodes	percent_of_prediction	percent_of_DWPC	metapath
Midodrine—Retinal vein occlusion—Vemurafenib—melanoma	0.114	0.192	CcSEcCtD
Midodrine—Hyperaesthesia—Bleomycin—melanoma	0.011	0.0186	CcSEcCtD
Midodrine—Scotoma—Carmustine—melanoma	0.00992	0.0168	CcSEcCtD
Midodrine—Scotoma—Temozolomide—melanoma	0.00959	0.0162	CcSEcCtD
Midodrine—Dry skin—Vemurafenib—melanoma	0.00948	0.016	CcSEcCtD
Midodrine—Hyperaesthesia—Temozolomide—melanoma	0.00928	0.0157	CcSEcCtD
Midodrine—Drug interaction—Carmustine—melanoma	0.00812	0.0138	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.0079	0.0134	CcSEcCtD
Midodrine—Hepatic enzyme increased—Temozolomide—melanoma	0.0077	0.013	CcSEcCtD
Midodrine—Heartburn—Docetaxel—melanoma	0.00703	0.0119	CcSEcCtD
Midodrine—Erythema multiforme—Vemurafenib—melanoma	0.00676	0.0115	CcSEcCtD
Midodrine—Cardiac disorder—Vemurafenib—melanoma	0.00664	0.0112	CcSEcCtD
Midodrine—Angiopathy—Vemurafenib—melanoma	0.00649	0.011	CcSEcCtD
Midodrine—Chills—Vemurafenib—melanoma	0.00642	0.0109	CcSEcCtD
Midodrine—Scotoma—Docetaxel—melanoma	0.00638	0.0108	CcSEcCtD
Midodrine—Back pain—Vemurafenib—melanoma	0.00602	0.0102	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00527	0.00892	CcSEcCtD
Midodrine—Drug interaction—Docetaxel—melanoma	0.00522	0.00884	CcSEcCtD
Midodrine—Nervous system disorder—Vemurafenib—melanoma	0.00498	0.00844	CcSEcCtD
Midodrine—Skin disorder—Vemurafenib—melanoma	0.00494	0.00836	CcSEcCtD
Midodrine—Dry skin—Temozolomide—melanoma	0.00484	0.0082	CcSEcCtD
Midodrine—Stomatitis—Bleomycin—melanoma	0.00471	0.00797	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.00446	0.00756	CcSEcCtD
Midodrine—Stomatitis—Dactinomycin—melanoma	0.00439	0.00743	CcSEcCtD
Midodrine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00439	0.00743	CcSEcCtD
Midodrine—Dysuria—Temozolomide—melanoma	0.00427	0.00723	CcSEcCtD
Midodrine—Pollakiuria—Temozolomide—melanoma	0.00422	0.00714	CcSEcCtD
Midodrine—Stomatitis—Carmustine—melanoma	0.00411	0.00696	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00404	0.00684	CcSEcCtD
Midodrine—Flushing—Bleomycin—melanoma	0.00402	0.00681	CcSEcCtD
Midodrine—Stomatitis—Temozolomide—melanoma	0.00397	0.00672	CcSEcCtD
Midodrine—Chills—Bleomycin—melanoma	0.00389	0.00658	CcSEcCtD
Midodrine—Hepatobiliary disease—Temozolomide—melanoma	0.00385	0.00652	CcSEcCtD
Midodrine—Erythema multiforme—Dactinomycin—melanoma	0.00382	0.00647	CcSEcCtD
Midodrine—Flushing—Dactinomycin—melanoma	0.00375	0.00635	CcSEcCtD
Midodrine—Asthenia—Vemurafenib—melanoma	0.00365	0.00617	CcSEcCtD
Midodrine—Chills—Dactinomycin—melanoma	0.00363	0.00614	CcSEcCtD
Midodrine—Urinary tract disorder—Temozolomide—melanoma	0.00361	0.00611	CcSEcCtD
Midodrine—Pruritus—Vemurafenib—melanoma	0.0036	0.00609	CcSEcCtD
Midodrine—Urethral disorder—Temozolomide—melanoma	0.00358	0.00607	CcSEcCtD
Midodrine—Flushing—Carmustine—melanoma	0.00351	0.00595	CcSEcCtD
Midodrine—Erythema multiforme—Temozolomide—melanoma	0.00346	0.00585	CcSEcCtD
Midodrine—Flushing—Temozolomide—melanoma	0.00339	0.00575	CcSEcCtD
Midodrine—Cardiac disorder—Temozolomide—melanoma	0.00339	0.00575	CcSEcCtD
Midodrine—Dizziness—Vemurafenib—melanoma	0.00336	0.00569	CcSEcCtD
Midodrine—Angiopathy—Temozolomide—melanoma	0.00332	0.00562	CcSEcCtD
Midodrine—Mental disorder—Carmustine—melanoma	0.00331	0.00561	CcSEcCtD
Midodrine—Chills—Temozolomide—melanoma	0.00328	0.00555	CcSEcCtD
Midodrine—Dry skin—Docetaxel—melanoma	0.00322	0.00545	CcSEcCtD
Midodrine—Rash—Vemurafenib—melanoma	0.0032	0.00543	CcSEcCtD
Midodrine—Mental disorder—Temozolomide—melanoma	0.0032	0.00542	CcSEcCtD
Midodrine—Dermatitis—Vemurafenib—melanoma	0.0032	0.00542	CcSEcCtD
Midodrine—Back pain—Carmustine—melanoma	0.00319	0.00539	CcSEcCtD
Midodrine—Headache—Vemurafenib—melanoma	0.00318	0.00539	CcSEcCtD
Midodrine—Confusional state—Bleomycin—melanoma	0.0031	0.00526	CcSEcCtD
Midodrine—Back pain—Temozolomide—melanoma	0.00308	0.00521	CcSEcCtD
Midodrine—Melatonin—CYP1B1—melanoma	0.00303	1	CrCbGaD
Midodrine—Agitation—Carmustine—melanoma	0.00303	0.00512	CcSEcCtD
Midodrine—Nausea—Vemurafenib—melanoma	0.00302	0.00511	CcSEcCtD
Midodrine—Agitation—Temozolomide—melanoma	0.00292	0.00495	CcSEcCtD
Midodrine—Hypertension—Carmustine—melanoma	0.00284	0.00481	CcSEcCtD
Midodrine—Anxiety—Carmustine—melanoma	0.00279	0.00473	CcSEcCtD
Midodrine—Paraesthesia—Bleomycin—melanoma	0.00276	0.00468	CcSEcCtD
Midodrine—Hypertension—Temozolomide—melanoma	0.00275	0.00465	CcSEcCtD
Midodrine—Dyspnoea—Bleomycin—melanoma	0.00275	0.00465	CcSEcCtD
Midodrine—Confusional state—Carmustine—melanoma	0.00271	0.00459	CcSEcCtD
Midodrine—Anxiety—Temozolomide—melanoma	0.0027	0.00457	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00269	0.00456	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Docetaxel—melanoma	0.00269	0.00455	CcSEcCtD
Midodrine—Dry mouth—Temozolomide—melanoma	0.00265	0.00449	CcSEcCtD
Midodrine—Stomatitis—Docetaxel—melanoma	0.00264	0.00447	CcSEcCtD
Midodrine—Pain—Bleomycin—melanoma	0.00263	0.00446	CcSEcCtD
Midodrine—Tachycardia—Carmustine—melanoma	0.00262	0.00444	CcSEcCtD
Midodrine—Confusional state—Temozolomide—melanoma	0.00262	0.00443	CcSEcCtD
Midodrine—Hepatobiliary disease—Docetaxel—melanoma	0.00256	0.00434	CcSEcCtD
Midodrine—Nervous system disorder—Temozolomide—melanoma	0.00255	0.00431	CcSEcCtD
Midodrine—Feeling abnormal—Bleomycin—melanoma	0.00254	0.0043	CcSEcCtD
Midodrine—Skin disorder—Temozolomide—melanoma	0.00252	0.00427	CcSEcCtD
Midodrine—Pain—Dactinomycin—melanoma	0.00246	0.00416	CcSEcCtD
Midodrine—Insomnia—Carmustine—melanoma	0.00243	0.00412	CcSEcCtD
Midodrine—Paraesthesia—Carmustine—melanoma	0.00241	0.00409	CcSEcCtD
Midodrine—Urinary tract disorder—Docetaxel—melanoma	0.0024	0.00407	CcSEcCtD
Midodrine—Dyspnoea—Carmustine—melanoma	0.0024	0.00406	CcSEcCtD
Midodrine—Somnolence—Carmustine—melanoma	0.00239	0.00405	CcSEcCtD
Midodrine—Urethral disorder—Docetaxel—melanoma	0.00238	0.00404	CcSEcCtD
Midodrine—Feeling abnormal—Dactinomycin—melanoma	0.00237	0.00401	CcSEcCtD
Midodrine—Insomnia—Temozolomide—melanoma	0.00235	0.00398	CcSEcCtD
Midodrine—Gastrointestinal pain—Dactinomycin—melanoma	0.00235	0.00398	CcSEcCtD
Midodrine—Paraesthesia—Temozolomide—melanoma	0.00233	0.00395	CcSEcCtD
Midodrine—Gastrointestinal disorder—Carmustine—melanoma	0.00232	0.00393	CcSEcCtD
Midodrine—Dyspnoea—Temozolomide—melanoma	0.00232	0.00392	CcSEcCtD
Midodrine—Somnolence—Temozolomide—melanoma	0.00231	0.00391	CcSEcCtD
Midodrine—Erythema multiforme—Docetaxel—melanoma	0.0023	0.00389	CcSEcCtD
Midodrine—Pain—Carmustine—melanoma	0.0023	0.00389	CcSEcCtD
Midodrine—Dyspepsia—Temozolomide—melanoma	0.00229	0.00387	CcSEcCtD
Midodrine—Abdominal pain—Dactinomycin—melanoma	0.00227	0.00384	CcSEcCtD
Midodrine—Flushing—Docetaxel—melanoma	0.00226	0.00382	CcSEcCtD
Midodrine—Cardiac disorder—Docetaxel—melanoma	0.00226	0.00382	CcSEcCtD
Midodrine—Gastrointestinal disorder—Temozolomide—melanoma	0.00224	0.0038	CcSEcCtD
Midodrine—Pain—Temozolomide—melanoma	0.00222	0.00376	CcSEcCtD
Midodrine—Feeling abnormal—Carmustine—melanoma	0.00221	0.00375	CcSEcCtD
Midodrine—Asthenia—Bleomycin—melanoma	0.00221	0.00374	CcSEcCtD
Midodrine—Angiopathy—Docetaxel—melanoma	0.00221	0.00374	CcSEcCtD
Midodrine—Gastrointestinal pain—Carmustine—melanoma	0.0022	0.00372	CcSEcCtD
Midodrine—Chills—Docetaxel—melanoma	0.00218	0.00369	CcSEcCtD
Midodrine—Pruritus—Bleomycin—melanoma	0.00218	0.00369	CcSEcCtD
Midodrine—Feeling abnormal—Temozolomide—melanoma	0.00214	0.00362	CcSEcCtD
Midodrine—Mental disorder—Docetaxel—melanoma	0.00213	0.00361	CcSEcCtD
Midodrine—Abdominal pain—Carmustine—melanoma	0.00212	0.0036	CcSEcCtD
Midodrine—Gastrointestinal pain—Temozolomide—melanoma	0.00212	0.0036	CcSEcCtD
Midodrine—Asthenia—Dactinomycin—melanoma	0.00206	0.00349	CcSEcCtD
Midodrine—Abdominal pain—Temozolomide—melanoma	0.00205	0.00348	CcSEcCtD
Midodrine—Back pain—Docetaxel—melanoma	0.00205	0.00347	CcSEcCtD
Midodrine—Muscle spasms—Docetaxel—melanoma	0.00203	0.00345	CcSEcCtD
Midodrine—Rash—Bleomycin—melanoma	0.00194	0.00329	CcSEcCtD
Midodrine—Dermatitis—Bleomycin—melanoma	0.00194	0.00328	CcSEcCtD
Midodrine—Asthenia—Carmustine—melanoma	0.00193	0.00327	CcSEcCtD
Midodrine—Asthenia—Temozolomide—melanoma	0.00186	0.00316	CcSEcCtD
Midodrine—Pruritus—Temozolomide—melanoma	0.00184	0.00311	CcSEcCtD
Midodrine—Nausea—Bleomycin—melanoma	0.00183	0.0031	CcSEcCtD
Midodrine—Hypertension—Docetaxel—melanoma	0.00183	0.00309	CcSEcCtD
Midodrine—Rash—Dactinomycin—melanoma	0.00181	0.00307	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00179	0.00303	CcSEcCtD
Midodrine—Dizziness—Carmustine—melanoma	0.00178	0.00301	CcSEcCtD
Midodrine—Dry mouth—Docetaxel—melanoma	0.00176	0.00298	CcSEcCtD
Midodrine—Confusional state—Docetaxel—melanoma	0.00174	0.00295	CcSEcCtD
Midodrine—Dizziness—Temozolomide—melanoma	0.00172	0.00291	CcSEcCtD
Midodrine—Nausea—Dactinomycin—melanoma	0.00171	0.00289	CcSEcCtD
Midodrine—Rash—Carmustine—melanoma	0.00169	0.00287	CcSEcCtD
Midodrine—Nervous system disorder—Docetaxel—melanoma	0.00169	0.00287	CcSEcCtD
Midodrine—Dermatitis—Carmustine—melanoma	0.00169	0.00287	CcSEcCtD
Midodrine—Tachycardia—Docetaxel—melanoma	0.00169	0.00285	CcSEcCtD
Midodrine—Headache—Carmustine—melanoma	0.00168	0.00285	CcSEcCtD
Midodrine—Skin disorder—Docetaxel—melanoma	0.00168	0.00284	CcSEcCtD
Midodrine—Rash—Temozolomide—melanoma	0.00164	0.00277	CcSEcCtD
Midodrine—Dermatitis—Temozolomide—melanoma	0.00164	0.00277	CcSEcCtD
Midodrine—Headache—Temozolomide—melanoma	0.00163	0.00276	CcSEcCtD
Midodrine—Nausea—Carmustine—melanoma	0.0016	0.0027	CcSEcCtD
Midodrine—Insomnia—Docetaxel—melanoma	0.00156	0.00265	CcSEcCtD
Midodrine—Paraesthesia—Docetaxel—melanoma	0.00155	0.00263	CcSEcCtD
Midodrine—Nausea—Temozolomide—melanoma	0.00154	0.00261	CcSEcCtD
Midodrine—Dyspnoea—Docetaxel—melanoma	0.00154	0.00261	CcSEcCtD
Midodrine—Somnolence—Docetaxel—melanoma	0.00154	0.0026	CcSEcCtD
Midodrine—Dyspepsia—Docetaxel—melanoma	0.00152	0.00257	CcSEcCtD
Midodrine—Gastrointestinal disorder—Docetaxel—melanoma	0.00149	0.00253	CcSEcCtD
Midodrine—Pain—Docetaxel—melanoma	0.00148	0.0025	CcSEcCtD
Midodrine—Feeling abnormal—Docetaxel—melanoma	0.00142	0.00241	CcSEcCtD
Midodrine—Gastrointestinal pain—Docetaxel—melanoma	0.00141	0.00239	CcSEcCtD
Midodrine—Abdominal pain—Docetaxel—melanoma	0.00137	0.00231	CcSEcCtD
Midodrine—Asthenia—Docetaxel—melanoma	0.00124	0.0021	CcSEcCtD
Midodrine—Pruritus—Docetaxel—melanoma	0.00122	0.00207	CcSEcCtD
Midodrine—Dizziness—Docetaxel—melanoma	0.00114	0.00193	CcSEcCtD
Midodrine—Rash—Docetaxel—melanoma	0.00109	0.00184	CcSEcCtD
Midodrine—Dermatitis—Docetaxel—melanoma	0.00109	0.00184	CcSEcCtD
Midodrine—Headache—Docetaxel—melanoma	0.00108	0.00183	CcSEcCtD
Midodrine—Nausea—Docetaxel—melanoma	0.00103	0.00174	CcSEcCtD
Midodrine—ADRA1D—Signaling Pathways—EDN1—melanoma	9.33e-05	0.00023	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CD—melanoma	9.32e-05	0.000229	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NGFR—melanoma	9.22e-05	0.000227	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AKT3—melanoma	9.22e-05	0.000227	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ITGAV—melanoma	9.22e-05	0.000227	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FGF1—melanoma	9.12e-05	0.000225	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CSF2—melanoma	9.12e-05	0.000225	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—IL2—melanoma	8.99e-05	0.000221	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HDAC2—melanoma	8.98e-05	0.000221	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FOXO4—melanoma	8.98e-05	0.000221	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CXCR4—melanoma	8.98e-05	0.000221	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—E2F1—melanoma	8.93e-05	0.00022	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CB—melanoma	8.89e-05	0.000219	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GNAQ—melanoma	8.88e-05	0.000218	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PDGFRA—melanoma	8.84e-05	0.000217	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ITGB3—melanoma	8.75e-05	0.000215	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PRKCA—melanoma	8.75e-05	0.000215	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—VCAN—melanoma	8.68e-05	0.000213	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SPP1—melanoma	8.58e-05	0.000211	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAP2K2—melanoma	8.55e-05	0.00021	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CG—melanoma	8.55e-05	0.00021	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—CXCL8—melanoma	8.54e-05	0.00021	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SOCS1—melanoma	8.54e-05	0.00021	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—MAP2K1—melanoma	8.52e-05	0.00021	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—S100B—melanoma	8.52e-05	0.00021	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CD—melanoma	8.46e-05	0.000208	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SYK—melanoma	8.34e-05	0.000205	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CD—melanoma	8.28e-05	0.000204	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ITGAV—melanoma	8.19e-05	0.000202	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AKT3—melanoma	8.19e-05	0.000202	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NGFR—melanoma	8.19e-05	0.000202	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—IL2—melanoma	8.16e-05	0.000201	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ERBB4—melanoma	8.15e-05	0.0002	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TERT—melanoma	8.13e-05	0.0002	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CB—melanoma	8.12e-05	0.0002	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—RAC1—melanoma	8.11e-05	0.0002	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CDKN2B—melanoma	8.07e-05	0.000199	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CD86—melanoma	7.81e-05	0.000192	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—CXCL8—melanoma	7.81e-05	0.000192	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HIF1A—melanoma	7.78e-05	0.000191	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EDN1—melanoma	7.75e-05	0.000191	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SOCS1—melanoma	7.58e-05	0.000187	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CSF2—melanoma	7.57e-05	0.000186	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FGF1—melanoma	7.57e-05	0.000186	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—MAP2K1—melanoma	7.57e-05	0.000186	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—S100B—melanoma	7.57e-05	0.000186	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CD—melanoma	7.52e-05	0.000185	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—IL2—melanoma	7.46e-05	0.000184	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KDR—melanoma	7.44e-05	0.000183	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—E2F1—melanoma	7.41e-05	0.000182	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CB—melanoma	7.38e-05	0.000182	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PDGFRA—melanoma	7.33e-05	0.00018	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP17A1—melanoma	7.32e-05	0.00018	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ITGB3—melanoma	7.26e-05	0.000179	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PRKCA—melanoma	7.26e-05	0.000179	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ERBB4—melanoma	7.24e-05	0.000178	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CB—melanoma	7.22e-05	0.000178	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CDKN2B—melanoma	7.17e-05	0.000176	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FN1—melanoma	7.16e-05	0.000176	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SPP1—melanoma	7.12e-05	0.000175	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAP2K2—melanoma	7.1e-05	0.000175	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—CXCL8—melanoma	7.09e-05	0.000174	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOTCH1—melanoma	7.01e-05	0.000172	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CD86—melanoma	6.94e-05	0.000171	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—CXCL8—melanoma	6.93e-05	0.000171	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GNA11—melanoma	6.91e-05	0.00017	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EDN1—melanoma	6.88e-05	0.000169	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CD80—melanoma	6.86e-05	0.000169	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—APC—melanoma	6.85e-05	0.000169	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KIT—melanoma	6.85e-05	0.000169	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CG—melanoma	6.85e-05	0.000169	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—NRAS—melanoma	6.85e-05	0.000169	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—IL2—melanoma	6.77e-05	0.000167	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EGF—melanoma	6.77e-05	0.000167	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—FASN—melanoma	6.76e-05	0.000166	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TERT—melanoma	6.75e-05	0.000166	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—RAC1—melanoma	6.73e-05	0.000166	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FGF1—melanoma	6.73e-05	0.000166	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CSF2—melanoma	6.73e-05	0.000166	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—SLC5A5—melanoma	6.65e-05	0.000164	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—IL2—melanoma	6.63e-05	0.000163	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—E2F1—melanoma	6.58e-05	0.000162	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—MAPK3—melanoma	6.56e-05	0.000161	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CB—melanoma	6.55e-05	0.000161	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PDGFRA—melanoma	6.51e-05	0.00016	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HIF1A—melanoma	6.45e-05	0.000159	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ITGB3—melanoma	6.45e-05	0.000159	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PRKCA—melanoma	6.45e-05	0.000159	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—BRAF—melanoma	6.44e-05	0.000158	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CD44—melanoma	6.43e-05	0.000158	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GNAQ—melanoma	6.43e-05	0.000158	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SPP1—melanoma	6.32e-05	0.000156	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAP2K2—melanoma	6.3e-05	0.000155	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CXCL8—melanoma	6.3e-05	0.000155	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IGF1—melanoma	6.27e-05	0.000154	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—MAPK1—melanoma	6.24e-05	0.000154	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—EGFR—melanoma	6.24e-05	0.000154	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KDR—melanoma	6.17e-05	0.000152	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP1B1—melanoma	6.16e-05	0.000152	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAP2K1—melanoma	6.06e-05	0.000149	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CD—melanoma	6.02e-05	0.000148	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—IL2—melanoma	6.02e-05	0.000148	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TERT—melanoma	6e-05	0.000148	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—RAC1—melanoma	5.98e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PIK3CA—melanoma	5.97e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FN1—melanoma	5.94e-05	0.000146	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—KRAS—melanoma	5.9e-05	0.000145	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOTCH1—melanoma	5.82e-05	0.000143	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FGF2—melanoma	5.77e-05	0.000142	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HIF1A—melanoma	5.73e-05	0.000141	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CD80—melanoma	5.7e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KIT—melanoma	5.69e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—APC—melanoma	5.69e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CG—melanoma	5.69e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—NRAS—melanoma	5.69e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EGF—melanoma	5.62e-05	0.000138	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KDR—melanoma	5.48e-05	0.000135	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—MAPK3—melanoma	5.45e-05	0.000134	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CA—melanoma	5.42e-05	0.000133	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MDM2—melanoma	5.4e-05	0.000133	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—BRAF—melanoma	5.35e-05	0.000132	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ERBB2—melanoma	5.32e-05	0.000131	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FN1—melanoma	5.28e-05	0.00013	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CB—melanoma	5.25e-05	0.000129	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IGF1—melanoma	5.21e-05	0.000128	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—MAPK1—melanoma	5.18e-05	0.000128	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—EGFR—melanoma	5.18e-05	0.000127	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOTCH1—melanoma	5.17e-05	0.000127	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ABCB1—melanoma	5.07e-05	0.000125	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CD80—melanoma	5.06e-05	0.000125	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CG—melanoma	5.05e-05	0.000124	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KIT—melanoma	5.05e-05	0.000124	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—APC—melanoma	5.05e-05	0.000124	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—NRAS—melanoma	5.05e-05	0.000124	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CXCL8—melanoma	5.05e-05	0.000124	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAP2K1—melanoma	5.03e-05	0.000124	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—HRAS—melanoma	5.01e-05	0.000123	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CD—melanoma	5e-05	0.000123	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EGF—melanoma	4.99e-05	0.000123	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CA—melanoma	4.95e-05	0.000122	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CDKN1B—melanoma	4.93e-05	0.000121	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—KRAS—melanoma	4.89e-05	0.00012	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—AKT1—melanoma	4.87e-05	0.00012	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—MAPK3—melanoma	4.84e-05	0.000119	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CASP3—melanoma	4.83e-05	0.000119	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL2—melanoma	4.82e-05	0.000119	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—IL6—melanoma	4.8e-05	0.000118	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FGF2—melanoma	4.79e-05	0.000118	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—BRAF—melanoma	4.75e-05	0.000117	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCND1—melanoma	4.7e-05	0.000116	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PRKCA—melanoma	4.67e-05	0.000115	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CTNNB1—melanoma	4.65e-05	0.000115	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ERCC2—melanoma	4.63e-05	0.000114	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IGF1—melanoma	4.62e-05	0.000114	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—MAPK1—melanoma	4.6e-05	0.000113	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—EGFR—melanoma	4.6e-05	0.000113	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MMP9—melanoma	4.56e-05	0.000112	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CDKN1A—melanoma	4.55e-05	0.000112	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PTEN—melanoma	4.54e-05	0.000112	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NFKB1—melanoma	4.51e-05	0.000111	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	4.5e-05	0.000111	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MDM2—melanoma	4.48e-05	0.00011	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAP2K1—melanoma	4.47e-05	0.00011	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CD—melanoma	4.44e-05	0.000109	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—AKT1—melanoma	4.43e-05	0.000109	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ERBB2—melanoma	4.42e-05	0.000109	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	4.4e-05	0.000108	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CB—melanoma	4.36e-05	0.000107	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—KRAS—melanoma	4.35e-05	0.000107	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FGF2—melanoma	4.25e-05	0.000105	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CXCL8—melanoma	4.19e-05	0.000103	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—HRAS—melanoma	4.16e-05	0.000102	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—VEGFA—melanoma	4.1e-05	0.000101	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CDKN1B—melanoma	4.09e-05	0.000101	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—STAT3—melanoma	4.06e-05	9.98e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NRAS—melanoma	4.05e-05	9.96e-05	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—AKT1—melanoma	4.05e-05	9.95e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CASP3—melanoma	4.01e-05	9.86e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL2—melanoma	4e-05	9.85e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	3.99e-05	9.83e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—IL6—melanoma	3.98e-05	9.8e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MDM2—melanoma	3.98e-05	9.79e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ERBB2—melanoma	3.92e-05	9.65e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCND1—melanoma	3.9e-05	9.6e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAPK3—melanoma	3.88e-05	9.54e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CB—melanoma	3.87e-05	9.52e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CTNNB1—melanoma	3.86e-05	9.51e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MMP9—melanoma	3.79e-05	9.32e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CDKN1A—melanoma	3.77e-05	9.29e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MYC—melanoma	3.77e-05	9.28e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PTEN—melanoma	3.77e-05	9.27e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NFKB1—melanoma	3.75e-05	9.22e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CXCL8—melanoma	3.72e-05	9.15e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—HRAS—melanoma	3.7e-05	9.09e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAPK1—melanoma	3.69e-05	9.08e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EGFR—melanoma	3.69e-05	9.07e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—AKT1—melanoma	3.67e-05	9.04e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CG—melanoma	3.66e-05	9e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CDKN1B—melanoma	3.63e-05	8.94e-05	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—AKT1—melanoma	3.59e-05	8.84e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CASP3—melanoma	3.56e-05	8.76e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL2—melanoma	3.55e-05	8.75e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—IL6—melanoma	3.54e-05	8.7e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PPARG—melanoma	3.53e-05	8.69e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KRAS—melanoma	3.48e-05	8.57e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCND1—melanoma	3.47e-05	8.53e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CTNNB1—melanoma	3.43e-05	8.44e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—VEGFA—melanoma	3.4e-05	8.37e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—STAT3—melanoma	3.37e-05	8.29e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MMP9—melanoma	3.36e-05	8.28e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NRAS—melanoma	3.36e-05	8.27e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CDKN1A—melanoma	3.35e-05	8.25e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PTEN—melanoma	3.34e-05	8.23e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NFKB1—melanoma	3.33e-05	8.19e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—AKT1—melanoma	3.26e-05	8.03e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAPK3—melanoma	3.22e-05	7.92e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CD—melanoma	3.22e-05	7.91e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CA—melanoma	3.2e-05	7.88e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALB—melanoma	3.17e-05	7.81e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MYC—melanoma	3.13e-05	7.7e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TP53—melanoma	3.1e-05	7.62e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAPK1—melanoma	3.06e-05	7.53e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EGFR—melanoma	3.06e-05	7.53e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—VEGFA—melanoma	3.02e-05	7.43e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—STAT3—melanoma	2.99e-05	7.36e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NRAS—melanoma	2.98e-05	7.34e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HRAS—melanoma	2.96e-05	7.29e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KRAS—melanoma	2.89e-05	7.11e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAPK3—melanoma	2.86e-05	7.03e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL6—melanoma	2.83e-05	6.97e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CB—melanoma	2.8e-05	6.9e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MYC—melanoma	2.78e-05	6.84e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTGS2—melanoma	2.78e-05	6.83e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAPK1—melanoma	2.72e-05	6.69e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EGFR—melanoma	2.72e-05	6.69e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CA—melanoma	2.66e-05	6.54e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—AKT1—melanoma	2.61e-05	6.43e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TP53—melanoma	2.57e-05	6.32e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KRAS—melanoma	2.57e-05	6.32e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HRAS—melanoma	2.46e-05	6.05e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTEN—melanoma	2.42e-05	5.96e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.36e-05	5.81e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL6—melanoma	2.35e-05	5.79e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TP53—melanoma	2.28e-05	5.62e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HRAS—melanoma	2.18e-05	5.37e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AKT1—melanoma	2.17e-05	5.34e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL6—melanoma	2.09e-05	5.14e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AKT1—melanoma	1.93e-05	4.74e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CA—melanoma	1.71e-05	4.2e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—AKT1—melanoma	1.4e-05	3.43e-05	CbGpPWpGaD
